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Abstract 
Background and Aim: Phage display technology provides a new approach for making human antibody fragments that 
could be applicable in passive immune therapy. We applied the use of this technology to make human single-chain 
variable fragments (scFvs) specific for tetanus toxin. Tetanus toxin is a neurotoxin constituted by the association of 
two subunits, mediates its lethal action by blocking neuromuscular vesicle docking.  
Methods: We previously found that six Human scFv clones inhibit toxin binding to ganglioside GT1b. This is the 
final report of human tetanus scFvs (scFv 8 and scFv 13) isolated from an immunized library of more than 106 scFv 
clones with in vivo neutralizing activity.  
Results: Only scFv 13 can reduce the in vivo toxicity induced by tetanus toxin. Also, scFv 8 has a weak capability of 
reducing the in vivo toxicity of the toxin.  
Conclusion: These selected ScFvs can be considered as a possible option to substitute the human tetanus 
immunoglobulin (HTIG) which is extensively current immunotherapy for tetanus patients. Taken together, our results 
suggest that the use of human tetanus scFvs may lead to a less aggressive passive immune therapy against tetanus. 
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Introduction 
Tetanus has remained an issue in developing 
countries (1). Tetanus toxin is a protein released by 
the bacterium Clostridium tetani that cause the 
disease symptoms(2). The tetanus neurotoxin 
(TeNT) is produced as a 150 kDa single 
polypeptide that is posted translationally cleaved to 
produce a 50 kDa light chain joined by a disulfide 
bond to a 100 kDa heavy chain (2). The heavy 
chain can be cleaved into two fragments (HN and 
HC) with distinct functions. It has been proven that 
the HC fragment is involved in binding to sensitive 
cells and subsequent internalization into vesicles. 
The HN fragment plays an important role in the 
translocation of the L-chain across the vesicular 
membrane (3). It has been proposed that the light 
chain reduces the secretion of the inhibitory 
neurotransmitter (glycine and GABA) from the 
inhibitory interneurons into the synaptic cleft by 
undergoing a retrograde transport via the nerve 
axon to the spinal cord and, thereby resulting in a 
spastic paralysis (2). 
Current management for tetanus includes TT-
containing vaccine and human tetanus 
immunoglobulin (HTIG) as immunotherapy (4-6). 
There are numerous limitations of the human-
derived immunoglobulin (7-10). Progress on 
recombinant antibody production has introduced 
new tools in the fields of therapeutic applications 
and provided an alternative to the hybridoma 
technology (11-14).  
Applying smaller antibody fragments have 
advantages over whole immunoglobulins for some 
clinical applications, such as toxin identification 
and detoxification, good penetration of solid 
tumors, and rapid clearance (15-17). Phage display 
has introduced a useful means to develop a 
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powerful method for the screening of libraries 
containing different peptides or proteins such as 
antibody fragments (11, 18-20). Currently, several 
therapeutic antibodies derived from phage display 
libraries are under clinical development (21-23). 
In this study, a previously contrasted human single-
chain fragment variable (HuscFv) phage library 
against anti-tetanus was assessed in mice model to 
find specific HuscFv antibodies against tetanus 
heavy chain(24). HuscFv phage was selected 
against TeNT and evaluated in vivo for its ability to 
neutralize the tetanus toxin. Now, we report the in 
vivo neutralizing potency of isolated scFvs specific 
for tetanus toxin from the large immunized phage 
display library described previously (24). After 
three rounds of panning, 15 scFv-phage clones 
displaying the desired specificity were obtained. 
High-affinity tetanus toxin neutralizing scFv maybe 
act as a therapeutic agent for alleviating the 
symptoms of tetanus toxin in infected individuals. 
We have constructed a panel of tetanus toxin-
neutralizing antibodies, including single-chain 
variable fragments (scFvs). The engendered panel 
of anti-tetanus scFvs compete with the cellular 
receptor for tetanus binding. Protection against 
tetanus toxin challenge in a mice model correlated 
strongly with affinity, with the highest-affinity 
antibody. 
Methods 
Engineering and Construction of phage 
Antibody library  
For this research, we applied the cloning and phage 
display system of previously constructed, which 
was quite satisfactory (24). To produce phage-scFv 
particles, 50 mL of E. coli TG1 transformants were 
cultured in 2xYT containing 100 mg/mL ampicillin 
and 1% glucose, shaking at 37ᵒC. At a culture 
density of OD600nm=0.5, 1012 pfu of M13KO7 
helper phage were added to the bacteria and left at 
37ᵒC with no shaking for 30 min followed by gentle 
shaking at 200 rpm for a further 30 min at 37C. The 
culture was then centrifuged and cell pellets were 
re-suspended in 50 mL of 2xTY containing 
50 mg/mL kanamycin and 100 mg/mL ampicillin 
and cultured overnight at 30ᵒC with shaking at 
250 rpm. The culture supernatant was centrifuged 
and 1:5 volume of ice-cold 20% PEG-6000 
containing 2.5 M NaCl was added and incubated on 
ice for at least 2 h to precipitate the phage particles, 
which were collected by centrifugation at 20,000 g 
for 2 h at 4ᵒC. The phage was stored at -80ᵒC in 
PBS containing 10% glycerol. Infective titers of 
phages-scFv were determined using plaque count 
assay. TG1 grown to mid-log phase in 2xYT 
medium was infected for 30 min at 37ᵒC with a 
serial dilution of the phage. The samples were 
spread on 2xYT plates containing 50 mg/mL 
kanamycin and incubated overnight at 37ᵒC. The 
number of plaques was used to calculate the phage 
titers. 
Screening of phage antibody library 
Selection of phage particles displaying specific 
scFv fragments was performed on Immuno 96 
MicroWellPlates (Nunc, Copenhagen, Denmark). 
TeNT used in this study was obtained from Razi 
Institute for Serums and Vaccines (Karaj, Iran). For 
the first panning round, 10 mg TeNT per well in 
100 mL PBS were coated in the microplates 
overnight at 4ᵒC. For more stringent conditions in 
the second and third rounds of panning 1 and 
0.1 mg TeNT per well were coated respectively. 
Following blocking with 5% (w/v) skim milk 
powder in PBS (5% MPBS), a library containing 
1012 phage particles was added and the microplate 
was incubated for 2 h at room temperature. Non-
bound phages were eliminated by washing 15 times 
with PBS containing 0.1% Tween-20 (PBST), 
followed by 15 times washing with PBS. The bound 
phages were eluted by incubation with 50 mL of 1 
mg/mL trypsin for 15 min. The second elution was 
followed by adding 50 mL of 50 mM glycine-HCl 
(pH 2.2) for 15 min at room temperature. Eluted 
phages of each step were used to infect 
exponentially growth of E. coli TG1 cells by 
incubating for 30 min at 37ᵒC. Infected cells were 
spread on 2xYT plate containing ampicillin 
(100 mg/mL) and glucose (1% w/v); the plate was 
incubated overnight at 37ᵒC. Individual phage-
infected clones were picked and grown for the 
production of phagemid particles. The culture was 
rescued using M13KO7 helper phage (Invitrogen, 
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Waltham, MA). Rescued phage particles were used 
to initiate another two subsequent rounds of 
selection using a similar procedure.  
Production of soluble scFv antibodies 
The selected scFv-phage was inoculated into the E. 
coli ER2738 non-suppressor strain. Transfected E. 
coli cells carrying the phagemid encoding the scFv 
antibody were grown in 2 mL of 2xYT medium 
containing ampicillin (100 mg/mL) and glucose 
(1% w/v) at 37ᵒC overnight. The overnight culture 
was used to inoculate 250 mL glucose-free 2XYT 
medium at 37ᵒC and 250 rpm until the OD600 nm 
reached 0.5. The scFv expression was induced by 1 
mM isopropyl b-D-1-thiogalactopyranoside (IPTG) 
for 7 h at 30ᵒC and 250 rpm. Cells were centrifuged 
and sonicated for scFv extraction. Purification of 
scFv fragments was performed using immobilized 
metal affinity chromatography (IMAC) under 
native conditions. All purified proteins were 
analyzed by reducing 15% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) 
followed by staining with Coomassie R-250. 
Western blot analysis was used to confirm the 
presence of His-tagged proteins at the correct 
molecular weight by anti-His-tag monoclonal 
antibody. 
Neutralization of the tetanus toxin effect by the 
soluble scFvs 
To evaluate the effect of scFvs on the lethality 
induced by tetanus toxin, two S.C LD50 of Tetanus 
toxin (10 ng) were preincubated with various 
concentrations of each scFv and injected into 22 g 
BALB/c mice. The mortality was followed every 24 
h during 14 days and the results are expressed as the 
rate of survival (hours) of mice 24 h after the 
Tetanus Toxin/ScFv injection.  
Results 
Engineering of anti-tetanus ScFv antibodies  
The heavy-chain (VH) and light-chain (VL) genes 
of antibodies were isolated by RT-PCR. Overlap 
extension PCR was used to produce 750 bp scFv 
gene fragments, with a sequence encoding the 
(Gly4Ser) 4 linker inserted between the C termini of 
the light chain sequences and the N termini of the 
heavy-chain sequences. The scFv genes were fused 
to the pIII protein in the vector Pcomb3x for display 
in a filamentous bacteriophage (Figure 1), and 
clones expressing the active protein were identified 
by phage enzyme-linked immunosorbent assay 
(ELISA). After expression and preliminary 
characterization of the scFv antibodies, 15 clones 
were entered to further studies (Figure 2a and 2b). 
 
Figure 1. SDS-PAGE analysis for detecting pIII-scFv 
in lysates of scfv-positive ER2738 E. coli clones. 
Clones 3 and 8, produced pIII-scFv shown as a band at 
53 kDa (arrows). Lane M, standard protein marker 
(value indicated at the left, in kilodaltons) 
Neutralization of the lethal potency of Tetanus 
Toxin 
Ten µg of the selected scFvs were incubated with 
80 ng concentration of Tetanus toxin, and the 
mixture was then injected into mice. Some of the 
scFvs studied showed a neutralizing activity. 
However, the protection observed was different 
from one scFv to another. Indeed, scFvs 8 and 13 
gave better protection than other scFvs (Table 1). 
The in vivo assay showed that the scFvs are specific 
for tetanus toxin. 
Neutralization of the lethal potency of CTX 
Different concentration of scFv1, scFv6, and scFv8 
were incubated with a ®xed concentration of CTX, 
and the mixture was then injected to mice. All the 
scFvs studied show a neutralizing activity.  
Tetanus Toxin (two s.c. LD50) was incubated with 
a fixed amount of each scFv (100 µg) as indicated 
in Materials and Methods. The mixture was injected 
into BALB/c mice and the mortality was followed 
every 24 hours. The results are expressed as the 
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Figure 2 a. SDS-PAGE analysis for detecting scFv in 
lysates of scfv-positive ER2738 E. coli clones. Clones 3, 
8, 13, 21, 23 and 23 produced scFv shown as double 
bands at *28–35 kDa (arrows). Lane M, standard protein 
marker (value indicated at the left, in kilodaltons). 
Figure 2b. Western blot analysis for detecting scFv in 
lysates of scfv-positive ER2738 E. coli clones detected 
with an anti-His tag antibody. Lane M, molecular mass 
marker (value indicated at the left, in kilodaltons). Lane 
ScFv, shown as double bands at 28–35 kDa (arrows). 
 
Table 1. Effect of scFv on the lethality induced by Tetanus Toxin 
Lifetime (Hour) Mice Numbers Injected Mixture 
24 3/3 ScFv  3 
56 3/3 ScFv  8 
30 2/2 ScFv  12 
140 3/3 ScFv  13 
24 2/2 ScFv  14 
24 2/2 ScFv  15 
24 2/2 ScFv  16 
30 2/2 ScFv  17 
30 2/2 ScFv  18 
24 2/2 ScFv  19 
30 2/2 ScFv  20 
24 2/2 ScFv  22 
36 2/2 ScFv  23 
24 2/2 ScFv 24 
24 3/3 Tetanus Toxin 
>200 3/3 PBS 
 
Discussion 
There is a growing demand for engineered proteins 
for therapeutic and diagnostic applications (25-28). 
Phage display technology has been successfully 
applied to produce antibody fragments that 
specifically bind to given antigens (29-32). In this 
study, we assessed the neutralizing ability of the 
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scFvs fragments library(24). To construct an 
antibody fragments library, the total mRNA was 
used from PBMCs of several donors who had 
received the booster tetanus vaccine. It has been 
shown that after boosting the affinity and specificity 
of antibodies are developed. We engineered the 
HuscFv format because the small size of scFv is 
well expressed in E. coli and typically high. (12). 
However, ScFv has rapid plasma clearance but 
exhibits high neutralizing ability.  
The previous results obtained from the TeNT 
binding inhibition assay implied that the HuscFv 
binds directly to the receptor-binding motif (24). 
Therefore, it can be deduced that selected HuscFv 
against heavy chain can be considered a useful and 
efficient approach in tetanus management. By the 
current study, the in vivo neutralizing efficacy of 
selected scFvs was assessed. Further investigations 
should be applied to assess a cocktail composed of 
scfv antibodies that recognize different epitopes of 
TeNT. To obtain scFv with greater affinities, we 
need to utilize mutagenesis by using error-prone 
PCR. It seems that our selected HuscFv antibodies 
could have been considered as a candidate to enroll 
in the other complementary studies against TeNT or 
an emerging diagnostic tool. 
Conclusion 
These selected ScFvs can be considered as a 
possible option to substitute the human tetanus 
immunoglobulin (HTIG) which is extensively 
current immunotherapy for tetanus patients. Taken 
together, our results suggest that the use of human 
tetanus scFvs may lead to a less aggressive passive 
immune therapy against tetanus. 
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